3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomach Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Neoplasm Metastasis
1
Metastatic Gastric Adenocarcinoma
1
Liver Neoplasms
1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Junction Adenocarcinoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Cisplatin
4
Paclitaxel
3
Vinblastine
2
Methotrexate
2
Gemcitabine
2
Doxorubicin
2
Carboplatin
2
cabozantinib
1
avelumab
1
Specimen Handling
1
Ramucirumab
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Fentanyl
1
Docetaxel
1
Disulfides
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urethral Neoplasms
×
Ramucirumab
×
Clear all
NCT02426125
2023-08-21
RANGE
Eli Lilly and Company
Phase 3
Completed
530 enrolled
22 charts